Kang Gagandeep
Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India.
Indian Pediatr. 2016 Jul 8;53(7):569-73. doi: 10.1007/s13312-016-0890-4.
Rotavirus was first identified as a human pathogen just over 40 years ago, and work on this pathogen in India started shortly thereafter. Subsequent studies have confirmed its pre-eminent role in gastroenteritis in children in India. Standardized surveillance has enabled the documentation of the high burden of disease, and has demonstrated that there is considerable geographic and temporal variation in strain circulation. Internationally licensed vaccines, vaccine candidates based on indigenous strains and out-licensed strains have been tested for safety, immunogenicity and efficacy; three vaccines are now licensed in India and are used in the private sector. Public sector vaccination has begun, and it will be path-breaking for Indian vaccinologists to measure impact of vaccine introduction in terms of safety and effectiveness. So far, India has kept pace with international epidemiologic and vaccine research on rotavirus, and these efforts should continue.
轮状病毒于40多年前首次被确认为一种人类病原体，此后不久印度就开始了对这种病原体的研究。随后的研究证实了它在印度儿童肠胃炎中所起的首要作用。标准化监测使得能够记录该疾病的高负担情况，并表明毒株传播存在相当大的地理和时间差异。已对国际许可疫苗、基于本土毒株和对外许可毒株的候选疫苗进行了安全性、免疫原性和有效性测试；目前有三种疫苗在印度获得许可并在私营部门使用。公共部门的疫苗接种已经开始，对印度疫苗学家来说，从安全性和有效性方面衡量疫苗引入的影响将是开创性的。到目前为止，印度在轮状病毒的国际流行病学和疫苗研究方面一直紧跟步伐，这些努力应该继续下去。
